Related references
Note: Only part of the references are listed.Laboratory Measurements of the Oral Direct Factor Xa Inhibitor Edoxaban Comparison of Prothrombin Time, Activated Partial Thromboplastin Time, and Thrombin Generation Assay
Yoshiyuki Morishima et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2015)
Antidotes for Novel Oral Anticoagulants Current Status and Future Potential
Mark Crowther et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review
Adam Cuker et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2015)
Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial
Christian T. Ruff et al.
LANCET (2015)
Targeted Anti-Anticoagulants
Kenneth A. Bauer
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity
Deborah M. Siegal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Guidelines for the Management of Spontaneous Intracerebral Hemorrhage A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
J. Claude Hemphill et al.
STROKE (2015)
Association of Apixaban Therapy and Prothrombin Time in Patients With Atrial Fibrillation - Single Center Cohort Study
Masashi Kanemoto et al.
CIRCULATION JOURNAL (2014)
Population Pharmacokinetics and Dose-Exposure Proportionality of Edoxaban in Healthy Volunteers
Ophelia Q. P. Yin et al.
CLINICAL DRUG INVESTIGATION (2014)
Phamacokinetics of rivaroxaban in adolescents
J. Beyer-Westendorf et al.
HAMOSTASEOLOGIE (2014)
Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents
B. J. Dale et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)
Use of PER977 to Reverse the Anticoagulant Effect of Edoxaban
Jack E. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Management of anticoagulant-related intracranial hemorrhage: an evidence-based review
Bappaditya Ray et al.
CRITICAL CARE (2014)
Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: Proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013
Gilles Pernod et al.
ARCHIVES OF CARDIOVASCULAR DISEASES (2013)
Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects
Charles Frost et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Reversing Dabigatran in Life-Threatening Bleeding Occurring During Cardiac Ablation With Factor Eight Inhibitor Bypassing Activity
William E. Dager et al.
CRITICAL CARE MEDICINE (2013)
Which test to use to measure the anticoagulant effect of rivaroxaban: the prothrombin time test
A. Tripodi
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
Robert P. Giugliano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide
Jonathan Douxfils et al.
THROMBOSIS AND HAEMOSTASIS (2013)
Monitoring plasma levels of factor Xa inhibitors: how, why and when?
Meyer-Michel Samama et al.
EXPERT REVIEW OF HEMATOLOGY (2013)
Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications
Alejandro Lazo-Langner et al.
CRITICAL CARE (2013)
In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux
Meyer Michel Samama et al.
THROMBOSIS RESEARCH (2012)
Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects
Elise S. Eerenberg et al.
CIRCULATION (2011)
Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability
Job Harenberg et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2011)
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers
Koichiro Ogata et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Share Paper
